VistaGen Noted in SF Chronicle for Toxicity Testing
Dear Friends of VistaGen:
The San Francisco Chronicle yesterday published an article on the front page of its Business section reporting on "Early Warning System for Drug Dangers Sought." The Chronicle is one of the leading newspapers covering the burgeoning biotech sector in California.
The article reports on "...a new generation of companies trying to update technology that detects whether new drugs may be harmful to the heart...."
The reporter, Bernadette Tansey, cites the Vioxx experience as accelerating the investigations.
VistaGen is noted prominently as one of three companies working actively in this area and showcases three photographs taken in our laboratory at corporate headquarters in South San Francisco.
We view this article as very positive for broadening awareness of our important drug toxicity testing toolkit using stem cell technology among pharmaceutical and biotech companies worldwide that are actively seeking to control their development cost and time for new drug development, as well as increase their success rates.
The article may be viewed on the San Francisco Chronicle/SFGate website at VistaGen Article or downloaded from the VistaGen website at VistaGen Download.
Best regards
-- Ralph
H. Ralph Snodgrass, Ph.D., CEO
VistaGen Therapeutics, Inc.
384 Oyster Point Blvd, #8
South San Francisco, CA 94080
(650) 244-9990 x222 (v)
(650) 244-9979 (f)
rsnodgrass@vistagen.com
www.vistagen.com
=====================================================
This message contains information that may be confidential and privileged. Unless you are the addressee (or authorized to receive for the addressee), you may not use, copy or disclose to anyone the message or any information contained in the message. If you have received the message in error, please advise the sender by reply e-mail, and delete this message. Thank you very much.
=====================================================
|
